Generation Bio (NASDAQ:GBIO) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Generation Bio (NASDAQ:GBIO) in a research note issued to investors on Friday,RTT News reports. The brokerage currently has a $5.00 price target on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Generation Bio in a report on Friday.

Generation Bio Stock Performance

Shares of Generation Bio stock opened at $0.48 on Friday. The company has a market capitalization of $32.06 million, a P/E ratio of -0.22 and a beta of 2.72. The company has a fifty day moving average of $0.74 and a 200 day moving average of $1.53. Generation Bio has a fifty-two week low of $0.47 and a fifty-two week high of $4.65.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%. Analysts forecast that Generation Bio will post -1.75 EPS for the current year.

Insider Buying and Selling at Generation Bio

In other Generation Bio news, Director Anthony G. Quinn purchased 85,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $0.97 per share, with a total value of $82,450.00. Following the acquisition, the director now owns 299,286 shares in the company, valued at approximately $290,307.42. The trade was a 39.67 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 21.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Intech Investment Management LLC bought a new position in shares of Generation Bio in the 4th quarter valued at about $25,000. Squarepoint Ops LLC bought a new position in shares of Generation Bio in the 4th quarter valued at about $70,000. Integrated Wealth Concepts LLC bought a new position in shares of Generation Bio in the 4th quarter valued at about $77,000. Barclays PLC lifted its holdings in shares of Generation Bio by 165.5% in the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock valued at $189,000 after acquiring an additional 47,639 shares during the last quarter. Finally, Aegis Wealth Management LLC bought a new position in shares of Generation Bio in the 4th quarter valued at about $94,000. Institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.